Rare diseases: Regulatory and reimbursement submissions, the challenges

Presented by

Dominic Tyer

About this talk

Companies developing new rare disease treatments face several unique challenges when it comes to their regulatory and reimbursement submissions. One of the most pressing of these is the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs), which form an important part of assessing signs and symptoms of rare diseases and treatment response.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (51)
Subscribers (7856)
This is a new service from PMGroup, who will be known to many in the pharmaceutical and healthcare industries for its well established portfolio of publications, awards schemes, live events and online offerings. Join us on our webinars to get connected with other thought leaders in healthcare